

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Avacopan for treating anti-neutrophil cytoplasmic
autoantibody-associated vasculitis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the draft scope consultation for TA308 [Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis](#), it was suggested that paediatric patients be included in the population and that there might be an increase in vasculitis in first or second generation immigrant populations.

During the development of TA308, the committee considered that cyclophosphamide reduces fertility in both men and women but understood that the peak age of onset for ANCA-associated vasculitis is between 60 and 70 years. The committee concluded that number of people with ANCA-associated vasculitis who have not completed their family is likely to be small.

No specific equality issues were raised for this topic

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee will discuss the impact of cyclophosphamide on fertility during the development of the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Linda Landells.....

Date: 17 August 2021